Are Patients with Schizophrenia Reliably Reporting their Cannabis Use? An African Cross-sectional Study.

Autor:	Rammouz I; Faculty of Medicine, Health Sciences Research Laboratory, Ibn Zohr University, Agadir, Morocco., Merzouki M; Faculté de Sciences et Techniques, Moulay Sliman University, Beni Mellal, Morocco., Bouri S; Faculty of Medicine, Clinical Neurosciences Laboratory, Sidi Mohamed Ben Abdellah University, Fez, Morocco., Rachid A; Faculty of Medicine, Clinical Neurosciences Laboratory, Sidi Mohamed Ben Abdellah University, Fez, Morocco., Bout A; Faculty of Medicine, Clinical Neurosciences Laboratory, Sidi Mohamed Ben Abdellah University, Fez, Morocco., Boujraf S; Faculty of Medicine, Clinical Neurosciences Laboratory, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Jazyk:	angličtina
Zdroj:	Central nervous system agents in medicinal chemistry [Cent Nerv Syst Agents Med Chem] 2022; Vol. 22 (3), pp. 188-197.
DOI:	10.2174/1871524922666220620150033
Abstrakt:	Background: Most studies of the prevalence of cannabis use among patients with schizophrenia used a self-report as declared by the patient himself. We hypothesize that patients with schizophrenia did not tell the truth and might underreport their use for many reasons to be discussed later. Indeed, the under-report of cannabis use among these patients can affect the effectiveness of their treatment. Aims: To assess the degree of agreement between the prevalence values obtained from patients' reports and the results of the toxicological tests. Methods: A cross-sectional study was carried out on 403 patients with schizophrenia. A sociodemographic, psychiatric history and illicit drug use profile was performed for each patient. We assessed the patients with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression score (CDSS), Barratt Impulsiveness Score (BIS-10) and Medication Adherence Rating Scale (MARS). The consumption of cannabis used was confirmed with MINI International Neuropsychiatric Interview (MINI-DSM IV) and using toxicological analysis. Results: Among the 403 patients who consented to give their urine samples, 49.1% (198/403) tested positive for cannabis, and 41.41% (82/198) underreported their use. The sensitivity and specificity of the questionnaire were 0.58 and 0.74. Based on the comparison between sociodemographic and psychiatric history data of patients who self-report and underreport their cannabis use, no significant difference was observed except for the duration of cannabis use and the score on the medication adherence scale. Moreover, it was found that impulsivity, PANSS score, CDSS score, and the type of schizophrenia are not involved in predicting the underreporting of cannabis use. Conclusion: The rate of patients who under-report cannabis use is important. Therefore, toxicological analysis is becoming relevant for identifying drug use among schizophrenic patients and in the addictive comorbidity research field. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu